XML 37 R18.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Segments of Business and Geographic Areas | 3 Months Ended
--- | ---
Mar. 31, 2024
Segment Reporting [Abstract] |
Segments of Business and Geographic Areas | Segments of business and geographic areas Following the separation of the Consumer Health business in the fiscal third quarter of 2023, the Company is now organized into two business segments: Innovative Medicine and MedTech. The segment results have been recast for all periods to reflect the continuing operations of the Company. Sales by segment of business
|  | Fiscal First Quarter Ended |  |
(Dollars in Millions) |  | March 31, 2024 |  | April 2, 2023 |  | Percent Change |  |  |  |  |  |
INNOVATIVE MEDICINE |  |  |  |  |  |  |  |  |  |  |  |
Immunology |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | $2,453 |  | 2,448 |  | 0.2 | % |  |  |  |  |  |
International |  | 1,794 |  | 1,664 |  | 7.9 |  |  |  |  |  |  |
Worldwide |  | 4,247 |  | 4,112 |  | 3.3 |  |  |  |  |  |  |
REMICADE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 266 |  | 276 |  | (3.9) |  |  |  |  |  |  |
U.S. Exports |  | 27 |  | 41 |  | (32.7) |  |  |  |  |  |  |
International |  | 141 |  | 170 |  | (17.2) |  |  |  |  |  |  |
Worldwide |  | 434 |  | 487 |  | (10.9) |  |  |  |  |  |  |
SIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 254 |  | 271 |  | (6.2) |  |  |  |  |  |  |
International |  | 299 |  | 266 |  | 12.4 |  |  |  |  |  |  |
Worldwide |  | 554 |  | 537 |  | 3.0 |  |  |  |  |  |  |
STELARA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,396 |  | 1,451 |  | (3.8) |  |  |  |  |  |  |
International |  | 1,055 |  | 993 |  | 6.2 |  |  |  |  |  |  |
Worldwide |  | 2,451 |  | 2,444 |  | 0.3 |  |  |  |  |  |  |
TREMFYA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 509 |  | 406 |  | 25.4 |  |  |  |  |  |  |
International |  | 299 |  | 234 |  | 27.9 |  |  |  |  |  |  |
Worldwide |  | 808 |  | 640 |  | 26.3 |  |  |  |  |  |  |
OTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 0 |  | 3 |  | * |  |  |  |  |  |
International |  | 0 |  | 0 |  | — |  |  |  |  |  |  |
Worldwide |  | 0 |  | 3 |  | * |  |  |  |  |  |
Infectious Diseases |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 324 |  | 392 |  | (17.4) |  |  |  |  |  |  |
International |  | 497 |  | 1,193 |  | (58.4) |  |  |  |  |  |  |
Worldwide |  | 821 |  | 1,586 |  | (48.3) |  |  |  |  |  |  |
COVID-19 VACCINE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 0 |  | 0 |  | — |  |  |  |  |  |  |
International |  | 25 |  | 747 |  | (96.6) |  |  |  |  |  |  |
Worldwide |  | 25 |  | 747 |  | (96.6) |  |  |  |  |  |  |
EDURANT / rilpivirine |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 8 |  | 9 |  | (10.9) |  |  |  |  |  |  |
|  | Fiscal First Quarter Ended |  |
(Dollars in Millions) |  | March 31, 2024 |  | April 2, 2023 |  | Percent Change |  |  |  |  |  |
International |  | 315 |  | 271 |  | 16.6 |  |  |  |  |  |  |
Worldwide |  | 323 |  | 280 |  | 15.7 |  |  |  |  |  |  |
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 314 |  | 378 |  | (16.9) |  |  |  |  |  |  |
International |  | 104 |  | 99 |  | 5.5 |  |  |  |  |  |  |
Worldwide |  | 418 |  | 477 |  | (12.3) |  |  |  |  |  |  |
OTHER INFECTIOUS DISEASES |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 2 |  | 5 |  | (68.8) |  |  |  |  |  |  |
International |  | 52 |  | 77 |  | (32.8) |  |  |  |  |  |  |
Worldwide |  | 53 |  | 82 |  | (35.1) |  |  |  |  |  |  |
Neuroscience |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,054 |  | 978 |  | 7.8 |  |  |  |  |  |  |
International |  | 749 |  | 826 |  | (9.3) |  |  |  |  |  |  |
Worldwide |  | 1,803 |  | 1,804 |  | 0.0 |  |  |  |  |  |
CONCERTA / methylphenidate |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 41 |  | 70 |  | (41.2) |  |  |  |  |  |  |
International |  | 136 |  | 136 |  | (0.1) |  |  |  |  |  |  |
Worldwide |  | 177 |  | 206 |  | (14.1) |  |  |  |  |  |  |
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 765 |  | 713 |  | 7.2 |  |  |  |  |  |  |
International |  | 292 |  | 331 |  | (11.8) |  |  |  |  |  |  |
Worldwide |  | 1,056 |  | 1,044 |  | 1.2 |  |  |  |  |  |  |
SPRAVATO |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 191 |  | 111 |  | 71.5 |  |  |  |  |  |  |
International |  | 34 |  | 20 |  | 76.1 |  |  |  |  |  |  |
Worldwide |  | 225 |  | 131 |  | 72.2 |  |  |  |  |  |  |
OTHER NEUROSCIENCE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 58 |  | 84 |  | (31.1) |  |  |  |  |  |  |
International |  | 287 |  | 339 |  | (15.5) |  |  |  |  |  |  |
Worldwide |  | 345 |  | 423 |  | (18.5) |  |  |  |  |  |  |
Oncology |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,383 |  | 1,889 |  | 26.2 |  |  |  |  |  |  |
International |  | 2,430 |  | 2,223 |  | 9.3 |  |  |  |  |  |  |
Worldwide |  | 4,814 |  | 4,112 |  | 17.1 |  |  |  |  |  |  |
CARVYKTI |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 140 |  | 70 |  | 99.8 |  |  |  |  |  |  |
International |  | 16 |  | 2 |  | * |  |  |  |  |  |
Worldwide |  | 157 |  | 72 |  | * |  |  |  |  |  |
DARZALEX |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,464 |  | 1,191 |  | 22.9 |  |  |  |  |  |  |
|  | Fiscal First Quarter Ended |  |
(Dollars in Millions) |  | March 31, 2024 |  | April 2, 2023 |  | Percent Change |  |  |  |  |  |
International |  | 1,228 |  | 1,072 |  | 14.5 |  |  |  |  |  |  |
Worldwide |  | 2,692 |  | 2,264 |  | 18.9 |  |  |  |  |  |  |
ERLEADA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 285 |  | 249 |  | 14.1 |  |  |  |  |  |  |
International |  | 404 |  | 293 |  | 38.0 |  |  |  |  |  |  |
Worldwide |  | 689 |  | 542 |  | 27.0 |  |  |  |  |  |  |
IMBRUVICA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 265 |  | 270 |  | (1.5) |  |  |  |  |  |  |
International |  | 518 |  | 557 |  | (7.0) |  |  |  |  |  |  |
Worldwide |  | 784 |  | 827 |  | (5.2) |  |  |  |  |  |  |
TECVAYLI(1) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 101 |  | 57 |  | 76.7 |  |  |  |  |  |  |
International |  | 33 |  | 6 |  | * |  |  |  |  |  |
Worldwide |  | 133 |  | 63 |  | * |  |  |  |  |  |
ZYTIGA / abiraterone acetate |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 9 |  | 16 |  | (41.3) |  |  |  |  |  |  |
International |  | 172 |  | 229 |  | (24.8) |  |  |  |  |  |  |
Worldwide |  | 181 |  | 245 |  | (25.9) |  |  |  |  |  |  |
OTHER ONCOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 119 |  | 35 |  | * |  |  |  |  |  |
International |  | 60 |  | 64 |  | (6.1) |  |  |  |  |  |  |
Worldwide |  | 178 |  | 99 |  | 80.2 |  |  |  |  |  |  |
Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 766 |  | 600 |  | 27.5 |  |  |  |  |  |  |
International |  | 283 |  | 272 |  | 4.1 |  |  |  |  |  |  |
Worldwide |  | 1,049 |  | 872 |  | 20.2 |  |  |  |  |  |  |
OPSUMIT |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 356 |  | 273 |  | 30.4 |  |  |  |  |  |  |
International |  | 169 |  | 167 |  | 0.8 |  |  |  |  |  |  |
Worldwide |  | 524 |  | 440 |  | 19.1 |  |  |  |  |  |  |
UPTRAVI |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 392 |  | 304 |  | 29.0 |  |  |  |  |  |  |
International |  | 76 |  | 58 |  | 30.7 |  |  |  |  |  |  |
Worldwide |  | 468 |  | 362 |  | 29.2 |  |  |  |  |  |  |
OTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 18 |  | 23 |  | (24.6) |  |  |  |  |  |  |
International |  | 39 |  | 47 |  | (16.9) |  |  |  |  |  |  |
Worldwide |  | 56 |  | 70 |  | (19.5) |  |  |  |  |  |  |
Cardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 631 |  | 715 |  | (11.7) |  |  |  |  |  |  |
International |  | 197 |  | 212 |  | (7.0) |  |  |  |  |  |  |
Worldwide |  | 829 |  | 927 |  | (10.6) |  |  |  |  |  |  |
|  | Fiscal First Quarter Ended |  |
(Dollars in Millions) |  | March 31, 2024 |  | April 2, 2023 |  | Percent Change |  |  |  |  |  |
XARELTO |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 518 |  | 578 |  | (10.4) |  |  |  |  |  |  |
International |  | — |  | — |  | — |  |  |  |  |  |  |
Worldwide |  | 518 |  | 578 |  | (10.4) |  |  |  |  |  |  |
OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 114 |  | 137 |  | (17.1) |  |  |  |  |  |  |
International |  | 197 |  | 212 |  | (7.0) |  |  |  |  |  |  |
Worldwide |  | 311 |  | 349 |  | (11.0) |  |  |  |  |  |  |
TOTAL INNOVATIVE MEDICINE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 7,612 |  | 7,023 |  | 8.4 |  |  |  |  |  |  |
International |  | 5,950 |  | 6,390 |  | (6.9) |  |  |  |  |  |  |
Worldwide |  | 13,562 |  | 13,413 |  | 1.1 |  |  |  |  |  |  |
MEDTECH |  |  |  |  |  |  |  |  |  |  |  |
Cardiovascular(2) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,025 |  | 863 |  | 18.8 |  |  |  |  |  |  |
International |  | 781 |  | 640 |  | 22.1 |  |  |  |  |  |  |
Worldwide |  | 1,806 |  | 1,503 |  | 20.2 |  |  |  |  |  |  |
ELECTROPHYSIOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 692 |  | 571 |  | 21.3 |  |  |  |  |  |  |
International |  | 652 |  | 522 |  | 24.9 |  |  |  |  |  |  |
Worldwide |  | 1,344 |  | 1,092 |  | 23.0 |  |  |  |  |  |  |
ABIOMED |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 303 |  | 264 |  | 15.0 |  |  |  |  |  |  |
International |  | 67 |  | 60 |  | 12.4 |  |  |  |  |  |  |
Worldwide |  | 371 |  | 324 |  | 14.5 |  |  |  |  |  |  |
OTHER CARDIOVASCULAR(2) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 30 |  | 28 |  | 3.3 |  |  |  |  |  |  |
International |  | 62 |  | 58 |  | 6.9 |  |  |  |  |  |  |
Worldwide |  | 92 |  | 87 |  | 5.7 |  |  |  |  |  |  |
Orthopaedics |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,448 |  | 1,363 |  | 6.2 |  |  |  |  |  |  |
International |  | 892 |  | 881 |  | 1.3 |  |  |  |  |  |  |
Worldwide |  | 2,340 |  | 2,245 |  | 4.3 |  |  |  |  |  |  |
HIPS |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 270 |  | 241 |  | 12.1 |  |  |  |  |  |  |
International |  | 152 |  | 149 |  | 1.7 |  |  |  |  |  |  |
Worldwide |  | 422 |  | 390 |  | 8.1 |  |  |  |  |  |  |
KNEES |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 242 |  | 226 |  | 6.9 |  |  |  |  |  |  |
International |  | 160 |  | 142 |  | 12.3 |  |  |  |  |  |  |
Worldwide |  | 401 |  | 368 |  | 9.0 |  |  |  |  |  |  |
|  | Fiscal First Quarter Ended |  |
(Dollars in Millions) |  | March 31, 2024 |  | April 2, 2023 |  | Percent Change |  |  |  |  |  |
TRAUMA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 504 |  | 491 |  | 2.8 |  |  |  |  |  |  |
International |  | 261 |  | 267 |  | (2.3) |  |  |  |  |  |  |
Worldwide |  | 765 |  | 757 |  | 1.0 |  |  |  |  |  |  |
SPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 432 |  | 406 |  | 6.5 |  |  |  |  |  |  |
International |  | 320 |  | 323 |  | (0.9) |  |  |  |  |  |  |
Worldwide |  | 752 |  | 729 |  | 3.2 |  |  |  |  |  |  |
Surgery |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 987 |  | 975 |  | 1.2 |  |  |  |  |  |  |
International |  | 1,429 |  | 1,459 |  | (2.0) |  |  |  |  |  |  |
Worldwide |  | 2,416 |  | 2,434 |  | (0.7) |  |  |  |  |  |  |
ADVANCED |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 446 |  | 444 |  | 0.2 |  |  |  |  |  |  |
International |  | 641 |  | 673 |  | (4.7) |  |  |  |  |  |  |
Worldwide |  | 1,087 |  | 1,118 |  | (2.8) |  |  |  |  |  |  |
GENERAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 542 |  | 531 |  | 2.1 |  |  |  |  |  |  |
International |  | 788 |  | 785 |  | 0.3 |  |  |  |  |  |  |
Worldwide |  | 1,330 |  | 1,316 |  | 1.0 |  |  |  |  |  |  |
Vision |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 547 |  | 558 |  | (1.8) |  |  |  |  |  |  |
International |  | 710 |  | 743 |  | (4.4) |  |  |  |  |  |  |
Worldwide |  | 1,258 |  | 1,300 |  | (3.3) |  |  |  |  |  |  |
CONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 438 |  | 444 |  | (1.4) |  |  |  |  |  |  |
International |  | 472 |  | 509 |  | (7.4) |  |  |  |  |  |  |
Worldwide |  | 910 |  | 953 |  | (4.6) |  |  |  |  |  |  |
SURGICAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 110 |  | 114 |  | (3.7) |  |  |  |  |  |  |
International |  | 238 |  | 233 |  | 2.2 |  |  |  |  |  |  |
Worldwide |  | 348 |  | 347 |  | 0.3 |  |  |  |  |  |  |
TOTAL MEDTECH |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 4,008 |  | 3,759 |  | 6.6 |  |  |  |  |  |  |
International |  | 3,813 |  | 3,722 |  | 2.4 |  |  |  |  |  |  |
Worldwide |  | 7,821 |  | 7,481 |  | 4.5 |  |  |  |  |  |  |
WORLDWIDE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 11,620 |  | 10,782 |  | 7.8 |  |  |  |  |  |  |
International |  | 9,763 |  | 10,112 |  | (3.4) |  |  |  |  |  |  |
Worldwide |  | $21,383 |  | 20,894 |  | 2.3 | % |  |  |  |  |  |
* Percentage greater than 100% or not meaningful (1)Previously included in Other Oncology (2) Previously referred to as Interventional Solutions Earnings before provision for taxes by segment
|  | Fiscal First Quarter Ended |  |  |
(Dollars in Millions) |  | March 31, 2024 |  | April 2, 2023 |  | Percent Change |  |  |  |  |  |  |  |  |  |  |
Innovative Medicine(1) |  | $4,969 |  | 4,402 |  | 12.9 | % |  |  |  |  |  |  |  |  |  |  |
MedTech(2) |  | 1,520 |  | 1,409 |  | 7.9 |  |  |  |  |  |  |  |  |  |  |  |
Segment earnings before provision for taxes |  | 6,489 |  | 5,811 |  | 11.7 |  |  |  |  |  |  |  |  |  |  |  |
Less: Expense not allocated to segments (3) |  | 2,775 |  | 7,098 |  |  |  |  |  |  |  |  |  |  |  |  |
Worldwide income (loss) before tax |  | $3,714 |  | (1,287) |  |  |  |  |  |  |  |  |  |  |  |  |
(1) Innovative Medicine includes: •Intangible amortization expense of $0.7 billion in both the fiscal first quarter of 2024 and 2023. •One-time COVID-19 Vaccine related exit costs of $0.4 billion in the fiscal first quarter of 2023. •A restructuring related charge of $0.1 billion in both the fiscal first quarter of 2024 and 2023. (2) MedTech includes: •Intangible amortization expense of $0.4 billion in both the fiscal first quarter of 2024 and 2023. (3) Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal first quarters of 2024 and 2023 include charges for talc matters of $2.7 billion and $6.9 billion, respectively (See Note 11, Legal Proceedings, for additional details). Sales by geographic area
|  | Fiscal First Quarter Ended |  |
(Dollars in Millions) |  | March 31, 2024 |  | April 2, 2023 |  | Percent Change |  |  |  |  |  |
United States |  | $11,620 |  | 10,782 |  | 7.8 | % |  |  |  |  |  |
Europe |  | 5,163 |  | 5,590 |  | (7.6) |  |  |  |  |  |  |
Western Hemisphere, excluding U.S. |  | 1,194 |  | 1,076 |  | 11.0 |  |  |  |  |  |  |
Asia-Pacific, Africa |  | 3,406 |  | 3,446 |  | (1.1) |  |  |  |  |  |  |
Total |  | $21,383 |  | 20,894 |  | 2.3 | % |  |  |  |  |  |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//280/tableOfContent Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration